LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

7.1 1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.03

Максимум

7.1

Ключови измерители
By Trading Economics
Приходи	7.8M 13M
Продажби	-4M 159M
Марж на печалбата	8.092
Служители	580
EBITDA	1.2M 30M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+171.79% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-95M 1.4B
Предишно отваряне	6.1
Предишно затваряне	7.1

Настроения в новините

By Acuity

41%

59%

129 / 374 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.11.2025 г., 21:36 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9.11.2025 г., 21:22 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10.11.2025 г., 00:00 ч. UTC

Пазарно говорене

India Inflation Poised to Hit New Low -- Market Talk

9.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9.11.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9.11.2025 г., 21:05 ч. UTC

Печалби

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9.11.2025 г., 21:04 ч. UTC

Печалби

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9.11.2025 г., 21:03 ч. UTC

Печалби

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8.11.2025 г., 13:10 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8.11.2025 г., 03:50 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8.11.2025 г., 03:41 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8.11.2025 г., 03:07 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

171.79% нагоре

12-месечна прогноза

Среден 19.27 USD 171.79%

Висок 30 USD

Нисък 8 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

129 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.